Investigating the effects of mesenchymal stromal cell vesicles on blood cell development in myelofibrosis patients
Official title: Microenvironment Cross-talk: Role of Extracellular Vesicles Derived From Mesenchymal Stromal Cells of Patients With Primary Myelofibrosis in Modifying Functional Activities of CD34+ Hematopoietic Progenitor Cells
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06896344 · Data updated 2026-11-12
This study is testing how special cells from patients with myelofibrosis affect the growth of blood cells to see if they behave differently than those from healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Drugs / interventions | Ruxolitinib |
| Locations | 1 site (Pavia, Pavia) |
| Status | Recruiting |
| Started | January 11, 2024 |
| Main results expected | June 2025 |
| Study ends | August 2025 |
| Registry record updated | April 2, 2025 |
| Trial ID | NCT06896344 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older diagnosed with primary myelofibrosis and carrying the JAK2 V617F mutation.
✕Probably not a fit
Patients with primary myelofibrosis who have undergone splenectomy or bone marrow transplant, or those with other concurrent pathologies, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore how mesenchymal stromal cells (MSCs) from patients with primary myelofibrosis (PMF) influence the maturation of CD34+ hematopoietic progenitor cells. The study will analyze the differences in MSCs from PMF patients compared to healthy donors and how these differences affect the signaling pathways involved in blood cell development. By utilizing in vitro cultures, the researchers will assess the impact of MSC-derived extracellular vesicles on CD34+ cells, particularly those expressing the JAK2 V617F mutation. The findings could provide insights into the bone marrow microenvironment's role in PMF pathology.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and potential new therapeutic strategies for managing primary myelofibrosis.
How similar studies have gone: While the specific approach of this study is novel, previous studies have shown the importance of MSCs in hematological malignancies, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with PMF * JAK2 V617F+ (either homozygous or heterozygous) * Out of therapy * At least 18 years old Exclusion Criteria: * PMF combined to other pathologies * Previous splenectomy * Previous bone marrow transplant
Where it's running
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, Italy Recruiting
Study contacts
- Principal investigator: Margherita Massa, PhD — IRCCS Policlinico San Matteo Foundation
- Study coordinator: Margherita Massa, PhD
- Email: m.massa@smatteo.pv.it
- Phone: +39 0382502703
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining Momelotinib and Luspatercept for Myelofibrosis Treatment
This study is testing if combining two medications, momelotinib and luspatercept, can help people with myelofibrosis who need blood transfusions feel better and reduce their transfusion needs.
-
MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.
Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.
-
Ruxolitinib given before, during, and after donor stem cell transplant for older adults with myelofibrosis or MDS/MPN overlap
This phase II test tries whether giving ruxolitinib before, during, and after an allogeneic stem cell transplant helps older adults with myelofibrosis or MDS/MPN overlap have better transplant outcomes and fewer complications like graft-versus-host disease.
-
National registry for people with myelofibrosis and anemia in Germany.
This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.
-
Comparing ASTX727 with and without Iadademstat for advanced blood cancers
This study is testing whether adding iadademstat to the ASTX727 treatment can help people with advanced blood cancers feel better and live longer compared to just using ASTX727 alone.
-
Observational study on ruxolitinib for myelofibrosis patients
This study looks at how well ruxolitinib works for people with myelofibrosis and how different factors affect their long-term survival.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.